Posttraumatic acute respiratory distress syndrome (ARDS) is associated with prolonged mechanical ventilation and longer hospitalizations. The relationship between posttraumatic ARDS severity and financial burden has not been previously studied. We hypothesized that increasing ARDS severity is associated with incrementally higher health care costs.
I
n the United States, injury is the leading cause of death for people aged 1 year to 44 years 1 and a leading cause of death worldwide. 2 The national economic burden of trauma is extensive as the total lifetime medical and work loss costs due to injury in the United States was estimated to be US $671 billion in 2013. 3, 4 There is a trimodal distribution of deaths after injury, 5, 6 with a significant proportion of late deaths due to multiorgan failure (MOF), 7, 8 frequently driven by lung dysfunction. 9 Since the initial recognition of acute lung injury as a clinical entity by Ashbaugh et al. 10 in 1967, it has undergone multiple iterations. Acute respiratory distress syndrome (ARDS) was formally defined at the American-European Consensus Conference in 1994 11 and most recently revised with the gradation of hypoxemia in the Berlin definition in 2012. 12 Acute respiratory distress syndrome is associated with significant morbidity and mortality in critically ill patients, with an estimated national incidence of 200,000 cases per year, representing nearly 15% of all intensive care unit (ICU) admissions and with a mortality ranging from 30% to 60%. [13] [14] [15] [16] The etiology of posttraumatic ARDS is hypothesized to be heterogeneous, related to both direct and indirect insults in addition to the complex milieu of systemic inflammation and infection. 17 A recent meta-analysis showed an estimated incidence of ARDS after injury of 8.4%, with no change in incidence over the past three decades despite a myriad of changes in trauma systems, patient management and public health priorities. 18 Further, lung injury after trauma continues to be associated with an extensive burden of mortality 19 with a nearly threefold higher mortality rate in critically ill severely injured patients. 20 Although there are no data specific to trauma patients regarding the cost associated with ARDS, the cost outcomes of patients suffering ARDS from primarily medical illness demonstrate that many die after protracted and costly treatment courses. [21] [22] [23] The incremental financial burden associated with increasing posttraumatic ARDS severity has not been previously studied. This study investigates the costs associated with posttraumatic ARDS and across ARDS categories classified by Berlin criteria.
MATERIALS AND METHODS
This study is a secondary analysis of a prospective cohort study of all highest-level activation trauma patients at a single urban Level I trauma center. Comprehensive demographic, injury, clinical, and outcome data were collected upon arrival and up to 28 days for 1,586 of the highest-level adult trauma activation subjects surviving more than six hours after injury from 2005 to 2016 at Zuckerberg San Francisco General Hospital. Patients were divided into those who developed ARDS by the Berlin criteria and compared with those without ARDS (see Supplemental Digital Content 1: Study Design Figure, http://links.lww.com/ TA/B137). Subset analyses were performed in intubated patients with and without ARDS (see Supplemental Digital Content 2 and 3, http://links.lww.com/TA/B137). Acute respiratory distress syndrome severity was classified by the degree of hypoxemia per the Berlin criteria: mild (200 < PaO 2 :FIO 2 ratio (P/F) ≤300), moderate (100 < P/F ≤ 200), and severe (P/F ≤ 100). 12 The Glasgow Coma Scale (GCS) scores used was the first recorded score in the emergency department. Multiorgan failure was defined using the Denver Postinjury Multiple Organ Failure Score. 24 Ventilator-free days were counted for the first 28 days of hospitalization. Subjects who expired received zero ventilator-free days.
To adjudicate the criteria of bilateral infiltrates, two expert critical care physicians blindly reviewed all chest x-rays (CXRs) from the first 8 days of care for enrolled subjects with a documented P/F ratio of 300 mgHg or lower. 25 Confirmation of P/F ratio of 300 mgHg or lower at time of positive CXR and positive end-expiratory pressure of 5 mm Hg or greater was performed on all subjects. Imaging studies were classified as "positive," "negative," or "equivocal" for the presence of bilateral infiltrates. "Equivocal" studies represented those images for which consensus could not be reached between expert reviewers. In the absence of volume overload or left heart failure, the time of onset of ARDS was determined as the first CXR adjudicated as "positive" for presence of bilateral infiltrates.
To exclude patients with CXR findings of bilateral infiltrates as a result of volume overload, left heart failure and volume status were adjudicated from echocardiogram reports and chart review. If an echocardiogram was performed for clinical care within 24 hours of the qualifying film for ARDS, reports were evaluated for the presence of moderate to severe left ventricular dysfunction or intravascular volume overload. If the subject did not have an echocardiogram performed, or if moderate systolic dysfunction was present, clinical records were reviewed for information regarding the clinical assessment of the presence of cardiogenic pulmonary edema. Subjects were excluded from analysis if cardiogenic pulmonary edema, gross volume overload requiring diuresis, or severe left ventricular systolic dysfunction was present.
Hospital charge data were used to perform standard costing analysis. Standard costing is a technique extrapolated from business where the practice of substituting an expected cost for an actual cost is done to benchmark future performance against or to compare current performance across groups. [26] [27] [28] [29] This analytic approach is commonly used in economic evaluations to minimize the effect of outliers and in situations where actual cost collection is challenging. In this method, data are grouped by common features to calculate the total cost for a group; either a mean per unit cost or a median cost can be calculated. This standardized cost is then applied to the members of the group to represent the expected cost for an episode of care for patients with a similar feature of interest. Variance or differences in cost are then able to be calculated between and within groups for comparisons.
Total hospital charges were used in this standardized costing analysis. Hospital charge data provides a relative measure of the "cost" of episodes of care, as actual cost data are generally not ascertainable in the health care setting. To estimate the median hospital charge per patient and minimize the effect of outliers due to prolonged and costly hospitalizations, we used this previously described standardized costing technique 26 through applying an expected daily standardized hospital charge to each patient's length of stay. The median standardized hospital charge was then analyzed by category to compare the attributable costs and differences related to ARDS development and by ARDS severity subtype.
Data are presented as mean (standard deviation), median (interquartile range), or percentage; univariate comparisons were made using Student's t test for normally distributed data, Wilcoxon rank sum or Kruskal-Wallis testing for nonparametric data, and Fisher's exact test for proportions. An [alpha] less than 0.05 was considered significant. All analyses were performed using Stata version 14 (StataCorp, College Station, TX). The study was approved by the institutional review board.
RESULTS

Total Cohort
During the 10-year study period, 1,586 subjects were enrolled in the study and survived at least 6 hours after injury. Overall, 34 subjects were excluded due to the development of respiratory failure attributable to left heart failure or cardiogenic pulmonary edema (n = 12), respiratory failure but equivocal CXR findings for bilateral infiltrates (n = 19), or presence of bilateral infiltrates without hypoxemia (n = 3). The remaining 1,552 patients were included in the analysis. The cohort was primarily male (82%), white (58%), and bluntly injured (57%) with one third (34%) diagnosed with traumatic brain injury (TBI). The mean age of subjects was 40 years, the median Injury Severity Score (ISS) was 13, and 28-day mortality was 13%. Overall, 53% were intubated on admission day. Acute respiratory distress syndrome diagnosed by Berlin criteria was present in 13% (203 of 1,586) of the cohort (Table 1) . Of the ARDS patients, 33% (n = 67) had mild hypoxemia (200 < P/F ≤ 300), 42% (n = 86) had moderate hypoxemia (100 < P/F ≤ 200), and 25% (n = 50) had severe hypoxemia (P/F ≤ 100).
Those subjects who developed ARDS were older (41 years vs. 35 years, p < 0.01), had higher median ISS (30 vs. 10, p < 0.01), and more suffered blunt mechanism of injury (85% vs. 53%; p < 0.01; Table 1 ). There was no difference in sex.
Acute respiratory distress syndrome subjects were both more likely to have any chest injury (median Abbreviated Injury Scale [AIS] score, 3 vs. 0; p < 0.01), severe chest injury (chest AIS score, ≥ 3: 51% vs. 21%, p < 0.01), suffered rib fractures (45% vs. 20%, p < 0.01) and nearly all were intubated on admission day (96% vs. 47%, p < 0.01). Subjects who developed ARDS had lower median GCS score on presentation (8 vs. 14, p < 0.01) and were more likely to have head injury (median head AIS score: 4 vs. 0, p < 0.01) and be diagnosed with TBI (67% vs. 28%, p < 0.01). Those who developed ARDS were more likely to be insured (77% vs. 62%, p < 0.01).
At presentation, subjects who developed ARDS had greater hemodynamic instability, with more subjects having tachycardia (admission heart rate >110 bpm: 44% vs. 26%; p < 0.01) and hypotension (admission systolic blood pressure, <90 mm Hg: 13% vs. 8%, p < 0.01). Those with ARDS had worsened acidosis at presentation (admit base excess: −6.8 vs. −3.1; p < 0.01) and were more likely to require any transfusion at both 6 hours (69% vs. 29%, p < 0.01) and 24 hours (74% vs. 33%, p < 0.01: Table 1 ). In comparing the 880 patients who were intubated during their clinical course, the subjects who developed ARDS still had more blunt injury, higher ISS, higher rates of all head and thoracic trauma injury, and were more likely to need transfusion at 6 hours and 24 hours (see Supplemental Digital Content 2, http://links.lww.com/TA/B137).
For those with ARDS, there was no difference in age, sex, body mass index (BMI), mechanism of injury, or presence of TBI by ARDS severity (Table 2 ). At presentation, there was also no difference in initial hemodynamics. With regard to torso trauma, there was no difference in median chest AIS score, proportion of subjects with any chest injury or severe chest injury, nor percentage of subjects with rib fractures. Although there was a statistically significant difference across ARDS severity by median ISS (mild, 29; moderate, 34; severe, 30; p = 0.04), in comparing the moderate to the severe ARDS group, there was no significant difference in ISS (p = 0.82). There was no difference in transfusion at 6 hours but there was a significant increase in receiving any transfusion at 24 hours by ARDS severity (mild, 64%; moderate, 76%; severe, 84%; p = 0.05).
Hospital Charges and Outcomes
Although there was no statistically significant difference in charge per day between those with and without ARDS, median actual total hospital charge was over threefold higher in subjects with ARDS (US $451,000 vs. US $106,000; p < 0.01). Standardized total hospital charges were fourfold higher in those with ARDS compared with those without (US $434,000 vs. US $96,000, p < 0.01; Table 3 ). This increase in overall hospital charges reflects the longer hospital (18 days vs. 4 days, p < 0.01) and ICU stays (14 days vs. 2 days, p < 0.01), and reflects the severity of illness of the ARDS patients (ventilator-free days, 3 days vs. 27 days, p < 0.01; MOF, 41% vs. 3%, p < 0.01). Acute respiratory distress syndrome patients had markedly higher mortality, with one third of ARDS patients deceased at 28 days (33%) and discharge (36%), compared with 10% of patients at both time points without ARDS (both p < 0.01). In comparing only patients who were intubated Table 4 ). Severe ARDS patients had increased mortality with half of the subjects with severe ARDS dying by 28 days (50%), compared with one third of those with moderate ARDS (33%) and almost a quarter of those with mild ARDS (21%, p < 0.01 for both). The total standardized hospital charge for the entire episode of care was therefore inversely related to ARDS severity (mild, US $580,000, moderate, US $495,000; severe, US $338,000; p < 0.01) because the number of hospital days were lower in the severe ARDS patients (p < 0.01). In fact, compared with those with mild/ moderate ARDS, those with severe ARDS had only 14 total hospital days versus 24 days for the mild group and 21 days for the moderate group (p < 0.01).
Impact of Survival Status on Hospital Charges
For those with ARDS, subgroup analyses were performed assessing the role of mortality on length of stay and cost. For ARDS survivors, there was no statistically significant difference by severity for hospital or ICU length of stay; there was also no difference in charge per day (Table 5 ). In contrast, for those ARDS patients deceased at discharge, there was a significant increase in charge per day by ARDS severity (mild, US $26,925; moderate, US $31,783; severe, US $43,380; p = 0.01; Table 6 ). Those with severe ARDS died sooner than those suffering mild or moderate ARDS, incurring less total hospital charges (mild, US $266,000; moderate, US $217,000; severe, US $121,000; p = 0.08), with a trend toward fewer hospital (mild/ moderate, 9 days; severe, 5 days; p = 0.10) and ICU days (mild, 11 days; moderate, 9 days; severe, 5 days; p = 0.08). In those without ARDS, we also investigated the impact of survival status on hospital costs and found that those who died were especially costly at US $38,801 per day. In contrast, those who survived without ARDS only cost US $22,476 per day.
DISCUSSION
The impact of ARDS on mortality after injury is well established; 7-9,11,12,24,30 however, there is no previous data in trauma patients focusing on the cost associated with developing posttraumatic ARDS by Berlin criteria. In this study, those who developed ARDS were more likely to be older, suffer blunt injury, be severely injured, and have severe chest and head injury. Similar to cost analyses in medical patients, ARDS patients in this study had significantly longer ICU and hospital stays and fewer ventilator-free days compared with those without ARDS. The net economic effect was higher total hospital charges in those with posttraumatic ARDS compared with patients without ARDS.
Using a standard costing approach, this study found that length of stay appears to be a major driver of the total health care Data are mean ± SD, median (interquartile range), or n (%) as indicated. Data for skewed variables reported as median with interquartile ranges. Ventilator-free days are counted for the first 28 days of hospitalization. Subjects who expired received 0 ventilator-free days. charges associated with ARDS. The net standardized charge per day between those with and without ARDS was not statistically different. This finding supports that length of stay is a potential modifiable driver of total cost of caring for ARDS patients. However, once one develops ARDS, there is a proportional increase in the charge per day that is incurred with increasing disease severity-especially in those who die during the index trauma hospitalization. It is likely that the increased charges per day are not only related to ARDS but also reflect the overall injury severity and critical illness after injury that contribute to the development and severity of ARDS. This is supported by the findings of increasing ISS, mortality, and incidence of MOF with worsening hypoxemia category by Berlin criteria. Unfortunately, injury factors are largely nonmodifiable because they are fixed by the initial injury pattern, and there is an increased cost of caring for sicker patients. 15, 31, 32 We initially hypothesized that ARDS patients would have higher costs per day due to apparent greater severity of illness by median ISS, increased need for transfusion, and incidence of severe TBI compared with the non-ARDS patients. However, our data demonstrated similar per day patient costs when analyzed in aggregate categories and therefore, we performed further subset analysis to elucidate the potential underlying contributing factors. The severe ARDS patient median cost per day exceeds that of the non-ARDS patients (severe ARDS, US $33,316 vs. non-ARDS, US $23,514), consistent with the finding of severe ARDS patients being more ill overall. In addition, when we further separated the non-ARDS patients by those who survived or died by discharge, a similar pattern was found wherein the nonsurvivors had markedly higher costs (US $38,801 vs. US $22,476); suggesting that degree of illness is the major driver of hospital costs. In addition, these non-ARDS patients included a higher percentage of penetrating trauma where ISS can often underrepresent severity of injury.
There are multiple interconnected factors that impact the cost of intensive care and ARDS. Unfortunately, when ARDS develops, care is largely supportive, and there are minimal modifiable risk factors identified thus far that can be changed to augment the disease course or decrease mortality in this patient population, despite many advances in modern critical care. This supportive ICU care expends a significant amount of hospital resources; patients in the ICU have higher total costs and longer lengths of stay than patients who do not require ICU care 33 and ICU care is estimated to be responsible for at least 13.4% of total yearly U.S. hospital costs. 34 In addition, critically ill patients who require mechanical ventilation incur an estimated national cost of $27 billion yearly, representing nearly one third of all ICU costs, 12% of all hospital costs and consume a significant proportion of hospital and critical care resources. 35 Studies on the outcomes and costs of ARDS have shown that the index ICU stay is responsible for much of the incremental cost associated with an episode of care. [36] [37] [38] Further, studies have shown that the majority of ICU costs are "fixed" and occur regardless of patient quantity and thoroughfare, making efforts to minimize cost fraught with institutional barriers and complexities. 39 Since the introduction of the Berlin definition, there is increasing literature regarding the epidemiology and outcomes of modern ARDS patients fulfilling the Berlin definition. Two studies have been recently published on the expected distribution of ARDS severity; a German-based cross sectional observational study 40 most frequently reported moderate ARDS (48%), followed by severe (38%) and mild (14%) disease. In contrast, a 41 reported a more even distribution of mild (30%), moderate (47%), and severe (23%) ARDS with an ARDS prevalence of 10.4% of ICU admissions and a nearly 40% mortality. Using blindly adjudicated chest radiograph findings, we found a similar distribution of ARDS severity with 33% of our patients suffering mild ARDS, 42% moderate, and 25% severe. Our mortality was also similar with 33% overall and 53% in the severe ARDS group.
Examining charges by ARDS severity is important given that similar to Bellani et al. we found those suffering severe ARDS died sooner and more often than those with mild or moderate disease. Thus, total hospital charges were lower due to the shorter overall hospital stays. If one were to only examine total hospital charges and not perform a standard costing analysis or a per unit charge analysis, the net economic impact of ARDS severity would be grossly underestimated. However, with standard costing, it is clear that these patients incur markedly more charges than those with less severe disease per unit of health care consumed as represented by the standard per day hospital charge. This is most prominently demonstrated by the effect of ARDS severity on hospital charges per day for patients who died with severe illness compared with mild or moderate illness.
Our study has several strengths including the rigorous adjudication of ARDS. We used a standardized costing approach which allows for understanding the effect of length of stay and associated procedures and minimizes the impact of outliers with lengthy or disproportionately costly hospitalizations. There is limited information regarding the cost of posttraumatic ARDS; prior cost analyses have also not assessed the impact of the Berlin categories on cost and hospital length of stay. This study is an important contribution toward defining the cost of ARDS development in trauma patients by severity and assessing the contributions of mortality and length of stay on resource utilization.
Our study has some limitations. It is a single-center study, and this may limit the generalizability of our findings, although the distribution of ARDS by severity category and noneconomic outcomes are consistent with the recent large study of ARDS patients in 50 countries by Bellani et al. 41 Although using absolute charges would not be translatable to other regions of the country and centers, a standard costing approach allows for comparison of expected to observed costs as a method of relative benchmarking similar to cost to charge ratios. While standardized costing analysis controls for important drivers of health care costs and is a well-accepted method to account for the total burden of resources required for an episode of care, it is not possible with this methodology to definitively demonstrate that ARDS is the isolated cause of the difference in standardized charges as we cannot describe the incremental cost of each potential risk factor and are limited to the goal of assessing only overall effect. Further, it is not possible due to limitations in the data to definitely conclude why the non-ARDS patients per day cost is similar. Importantly, only select operative data were collected, and it is possible that the non-ARDS patients required either more interventions overall or costlier operative interventions, such as orthopedic surgeries with hardware. Because ARDS is associated with increasing injury severity, the charge difference also likely reflects in part the differences in the care rendered for specific injuries and increased severity. Additionally, our hospital system is limited in providing only summary total hospital charges and not itemized charges for each patient; therefore, we are unable to determine incremental breakdown of costs related to the total hospital charge, which would be an important analysis in assessing interventions to reduce the costs of care.
CONCLUSION
The development of posttraumatic ARDS is associated with higher health care costs. Among trauma patients who develop ARDS, hospital charges per day increase with worsening severity of disease and hypoxemia. The majority of factors contributing to the development or severity of posttraumatic ARDS are nonmodifiable risk factors. The only modifiable risk factors identified for the development or severity of ARDS were transfusion variables within the first 24 hours. Given the profound morbidity and mortality associated with posttraumatic ARDS, ongoing investigations of ideal transfusion parameters and practices in the era of balanced resuscitation will be critical to alleviating the cost and burden of ARDS in trauma populations. Further, protective strategies to prevent or mitigate ARDS after trauma are essential to controlling health care costs and should be prioritized. 
